Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ChemoCentryx

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases

• Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2

• Anticipated life expectancy ≥ 12 weeks

• Radiographically measurable disease acc. to RECIST 1.1

• Use of adequate contraception (as described in protocol)

• Ability to provide written informed consent and comply with study requirements

Exclusion Criteria:

• Received other cancer treatment or investigational drug within 4 weeks prior to screening

• Women who are pregnant or breastfeeding

• Had major surgery within 4 weeks of first dose of study drug

• Inadequate liver, renal or bone marrow function within 2 weeks of first dose

• Serious concurrent illness, altered medical status or any uncontrolled medical condition

• Any infection requiring antibiotic or anti-viral treatment within 4 weeks of screening

• Known active HIV, HBV or HCV infection

• Inability to swallow tablets

• History or presence of any medical condition or disease which, in the opinion of the investigator, may place the subject at unacceptable risk for study participation